Skip to main content
Search
Search
Anywhere
Quick Search anywhere
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Search
Advanced Search
Login
Skip main navigation
Open Drawer Menu
Close Drawer Menu
Home
Journal of Comparative Effectiveness Research
Journal of Patient Centricity
The Evidence Base
Skip slideshow
Journal of Comparative Effectiveness Research
ISSN (print): 2042-6305 • ISSN (online): 2042-6313
Impact Factor: 2.8 (2025) • CiteScore: 4.2 (2025) • Open Access
Read more
Journal of Patient Centricity
ISSN (online): 2978-8579
In partnership with the PCSIG • Open Access
Read more
The Evidence Base
Latest news, opinion and insight into hot topics including RWE, HEOR, HTA and market access
Read more
Latest
US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes
Adam Kasle
,
Devin Abrahami
,
David Veenstra
,
Robert Morlock
,
Priya Ramachandran
,
Lindsay Stansfield
, and
Raymond Mak
Journal of Comparative Effectiveness Research
3 Sep 2026
Prognostic value of liver histology in steatotic liver disease: a systematic literature review and meta-analysis
A Sidney Barritt
,
Anila Qasim
,
Yestle Kim
,
Sally D Miller
,
John O'Donnell
, and
Karissa Johnston
Journal of Comparative Effectiveness Research
3 Sep 2026
ISPE 2026: Externally controlled trials under scrutiny for regulatory decision-making
The Evidence Base
3 Sep 2026
FDA invites sponsors to seek early RWE advice through Advancing Real-World Evidence Program
The Evidence Base
3 Sep 2026
Journal of Comparative Effectiveness Research
Open access, peer-reviewed journal offering rapid publication for all aspects of HEOR and related areas
Read More
FROM THE EVIDENCE BASE
3 Sep 2026
ISPE 2026: Externally controlled trials under scrutiny for regulatory decision-making
3 Sep 2026
FDA invites sponsors to seek early RWE advice through Advancing Real-World Evidence Program
3 Sep 2026
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– September 2026
1 Sep 2026
ISPOR Asia Pacific Summit 2026 preview: Four questions shaping the future of health innovation
31 Aug 2026
Maprium and Vitaccess partner on managed access programs and real-world evidence
28 Aug 2026
Market access and HTA developments with Sreeram Ramagopalan: Prior authorization barriers and cost-effectiveness thresholds
3 Sep 2026
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– September 2026
2 Sep 2026
Real-world study finds tirzepatide associated with lower healthcare costs in adults over 55 with obesity
1 Sep 2026
Trump Administration announces nine new MFN drug pricing agreements
The Evidence Base
Online hub providing the latest news, opinion and insights into HEOR, RWE, HTA and more
Read More
FROM THE EVIDENCE BASE
3 Sep 2026
ISPE 2026: Externally controlled trials under scrutiny for regulatory decision-making
3 Sep 2026
FDA invites sponsors to seek early RWE advice through Advancing Real-World Evidence Program
3 Sep 2026
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– September 2026
3 Sep 2026
ISPE 2026: What ATMPs demand from post-marketing evidence generation
.png)
.png)
